HUTCHMED (NASDAQ:HCM) Stock Price Passes Below Fifty Day Moving Average – What’s Next?

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM)’s stock price passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $14.69 and traded as low as $14.32. HUTCHMED shares last traded at $14.33, with a volume of 19,957 shares traded.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Wall Street Zen upgraded HUTCHMED from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. Jefferies Financial Group upgraded shares of HUTCHMED to a “strong-buy” rating in a research report on Monday, January 19th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of HUTCHMED in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, HUTCHMED presently has an average rating of “Hold” and a consensus target price of $20.88.

HUTCHMED Price Performance

The company has a 50-day moving average of $14.69 and a 200-day moving average of $15.05. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.65 and a quick ratio of 4.51.

Hedge Funds Weigh In On HUTCHMED

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Blue Trust Inc. raised its stake in shares of HUTCHMED by 131.5% in the 4th quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock valued at $103,000 after purchasing an additional 4,378 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of HUTCHMED by 4.7% during the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after buying an additional 698 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its position in HUTCHMED by 12.1% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,363 shares of the company’s stock valued at $273,000 after buying an additional 1,873 shares during the last quarter. Bank of America Corp DE lifted its stake in HUTCHMED by 17.3% in the 2nd quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after acquiring an additional 3,035 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in HUTCHMED by 34.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock worth $342,000 after acquiring an additional 5,538 shares during the last quarter. 8.82% of the stock is owned by institutional investors and hedge funds.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.